DAE HWA Pharmaceutical Co., Ltd. Stock: price and insider trades · South Korea
대화제약
1 insider bought €9,173 of shares over the last 90 days, the latest by 김은석, filed 22 Sept 2026.
Who traded when
BuySaleSince the insiders bought
- -15.6%Entry ₩12,490 · Close at T+90 ₩10,545
- +36.9%Entry ₩12,910 · Close at T+365 ₩17,670
- +33.5%Entry ₩10,350 · Close at T+365 ₩13,820
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- 1,300 sharesShareKRXDART:20260922000153Canonical exit: 21 Dec 2026 (T+90)
- 1,500 sharesShareKRXDART:20260922000152
- Other0DART
- 1,600 sharesShareKRXDART:20260730000199Canonical exit: 28 Oct 2026 (T+90)
- Other0DART
- 4,600 sharesShareKRXDART:20260702000176Canonical exit: 30 Sept 2026 (T+90)
- 11,531 sharesShareKRXDART:20260612000371Canonical exit: 10 Sept 2026 (T+90)
- 2,319 sharesShareKRXDART:20260528000282Canonical exit: 16 Aug 2026 (T+90)
- 1,000 shares@ ₩13,650.5080.0075% mcapShareKRXDART:20260528000292Canonical exit: 28 Jul 2025 (T+90)
- 1,750 shares@ ₩14,648.73140.016% mcap15.8% of flowShareKRXDART:20260514000589Canonical exit: 26 Jul 2026 (T+90)
- 3,500 shares@ ₩14,893.000.027% mcap100.0% of flowShareKRXDART:20260424000433
- 1,000 shares@ ₩13,909.730.0072% mcap8.5% of flowShareKRXDART:20260421000391Canonical exit: 13 Jul 2026 (T+90)
- 4,450 shares@ ₩14,758.83690.034% mcap40.5% of flowShareKRXDART:20260327000820Canonical exit: 17 Jun 2026 (T+90)
- 3,550 shares@ ₩14,228.93670.030% mcap35.2% of flowShareKRXDART:20260312000426
- ●Executives0DART
- 95,900 sharesKRXDART:20260107000533
- 7,000 sharesShareKRXDART:20251216000181
- ●Executives0DART
- 5,000 sharesShareKRXDART:20251001000358
- 35,000 sharesShareKRXDART:20251001000390
- 3,000 sharesShareKRXDART:20250805000176
- 7,000 sharesShareKRXDART:20250423000522
- 2,500 sharesShareKRXDART:20250423000519
- ●Executives0DART
25 of 135 declarations
About DAE HWA Pharmaceutical Co., Ltd.
With 132 filings from 8 filers, 대화제약 (DAE HWA Pharmaceutical Co., Ltd.) has a voluminous record, mostly sales: 35, against 20 purchases (36% purchases). Two honorary chairmen (명예회장) are the source: 김수지 files 87, with one purchase and 14 sales, and 김운장 16 sales, the only one with an amount being EUR 29,868 on April 17, 2026.
Purchases come mainly from 김은석 (대표이사): 14 purchases out of 15 filings, including EUR 38,027 on March 19, 2026, EUR 14,817 on April 27, 2026 and EUR 9,026 on December 19, 2022. Seven purchases carry an amount, EUR 91,500 in all (median EUR 9,002). 방신원 (상무) signs 2. The 2 filers in the window from March 28 to April 15, 2024 bought together.
Read moreShow less
A South Korean health care company with a KRW 190.7 billion capitalisation and 26.7% held by insiders. The yearly volume rises to 35 filings in 2024, after 21, 19 and 28 in the three previous years, then 15 and 14. For 12 purchases, a 90-day median of minus 7.9%, with 42% of results positive (recorded past results, not a forecast).
